WEBULL
WebtradeDownload

Ambu Stock In Focus After Full Year Earnings And Dividend Announcement

Simply Wall St · 10h ago
  • Ambu reported full year 2026 results with sales of DKK 6,471 million and net income of DKK 642 million, and declared an annual dividend of DKK 0.56 per share payable on December 7, 2026.
  • The combination of higher reported earnings per share from continuing operations and a set cash return through the dividend puts Ambu’s operating performance and capital allocation choices in sharper focus for investors who are assessing the business mix shift toward Endoscopy Solutions.
  • We will examine how Ambu’s investment narrative is influenced by the higher full year earnings and the newly announced cash dividend.
Capture how Ambu’s dividend and earnings story compares to other income ideas by scanning a curated list of 220 dividend fortresses with resilient cash flows and payouts.

Ambu Investment Narrative Recap

To own Ambu, you need to believe the single use endoscopy story still has a long runway and that the tilt toward Endoscopy Solutions keeps supporting earnings quality. The latest full year numbers show sales of DKK 6,471 million and net income of DKK 642 million, which keeps the operational debate focused on execution rather than survival.

In the near term, the key swing factor remains how quickly hospitals keep converting from reusable scopes, while Anesthesia and Patient Monitoring stays at very low single digit growth. The analyst consensus Narrative on Simply Wall St still highlights FX and U.S. tariffs as live risks. The new dividend does not materially change those operational pressure points.

The annual dividend of DKK 0.56 per share is the clearest new data point. For income focused holders, a defined cash payout signals that Ambu is comfortable returning some capital while still funding scope development, EndoIntelligence and manufacturing optimisation. It also gives you a hard cash figure to compare with other healthcare income ideas rather than just relying on projected growth.

That dividend only looks sustainable if the core thesis around Endoscopy Solutions mix, pricing discipline in Anesthesia and Patient Monitoring, and factory efficiency remains intact. Currency volatility, tariffs and softer anesthesia volumes are still the main threats to that cash generation story. When you line Ambu up against other dividend stocks with steadier cash flows, this is less a pure income play and more an operating momentum plus modest payout combination.

What Ambu’s Forecasts Assume About Growth And Income

Ambu's narrative projects DKK 8.7 billion revenue and DKK 1.1 billion earnings by 2029. This assumes 11.6% yearly revenue growth and roughly a DKK 590 million earnings increase from current earnings of DKK 510.0 million.

Uncover why Ambu's fair value indicates a 12% potential downside to its current price, which leaves little room for error.

CPSE:AMBU B 1-Year Stock Price Chart
CPSE:AMBU B 1-Year Stock Price Chart

Exploring Other Perspectives

One optimistic twist in the alternate Ambu story is free cash flow. Before this dividend and earnings update, the most positive analysts were already modelling DKK 9.0 billion revenue and DKK 1.2 billion earnings by 2029. You can treat this new payout as a fresh test of those upbeat expectations and explore how your own view lines up.

Explore 2 other Ambu fair value estimates, including one that suggests as much as 23% upside from the current price.

Reach Your Own Conclusion

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

Looking for more Ambu-like investment ideas?

If Ambu has sharpened your focus on earnings quality and cash returns, it can help to line it up against a broader watchlist of companies with different strengths. The Simply Wall St Screener lets you scan the market using the same kind of filters you have been applying here, so you can build a shortlist that fits your own income, quality or value priorities.